Jean-Yves Winum

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8711442/publications.pdf

Version: 2024-02-01

195	8,300	41344	54911
papers	citations	h-index	g-index

224	224	224	6185
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Research, 2011, 71, 3364-3376.	0.9	662
2	Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics. Oncotarget, 2012, 3, 84-97.	1.8	365
3	Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene, 2013, 32, 5210-5219.	5.9	287
4	Glycosyl Coumarin Carbonic Anhydrase IX and XII Inhibitors Strongly Attenuate the Growth of Primary Breast Tumors. Journal of Medicinal Chemistry, 2011, 54, 8271-8277.	6.4	228
5	Carbonic anhydrase IX: A new druggable target for the design of antitumor agents. Medicinal Research Reviews, 2008, 28, 445-463.	10.5	210
6	Carbonic Anhydrase Inhibitors. Design of Fluorescent Sulfonamides as Probes of Tumor-Associated Carbonic Anhydrase IX That Inhibit Isozyme IX-Mediated Acidification of Hypoxic Tumorsâ€. Journal of Medicinal Chemistry, 2005, 48, 4834-4841.	6.4	205
7	Sulfamates and their therapeutic potential. Medicinal Research Reviews, 2005, 25, 186-228.	10.5	191
8	Therapeutic potential of sulfamides as enzyme inhibitors. Medicinal Research Reviews, 2006, 26, 767-792.	10.5	173
9	Antimetastatic Effect of Sulfamate Carbonic Anhydrase IX Inhibitors in Breast Carcinoma Xenografts. Journal of Medicinal Chemistry, 2012, 55, 5591-5600.	6.4	149
10	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 231-234.	2.2	147
11	Carbonic Anhydrase Inhibitors:â€‰ Clash with Ala65 as a Means for Designing Inhibitors with Low Affinity for the Ubiquitous Isozyme II, Exemplified by the Crystal Structure of the Topiramate Sulfamide Analogue. Journal of Medicinal Chemistry, 2006, 49, 7024-7031.	6.4	147
12	Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 2197-2204.	6.4	138
13	Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3102-3108.	2.2	137
14	Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Medicinal Chemistry, 2015, 7, 1407-1414.	2.3	135
15	Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. Metabolites, 2020, 10, 412.	2.9	116
16	Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Medicinal Research Reviews, 2009, 29, 419-435.	10.5	104
17	Cloning, Characterization, and Inhibition Studies of a Î²-Carbonic Anhydrase from Brucella suis. Journal of Medicinal Chemistry, 2010, 53, 2277-2285.	6.4	104
18	Carbonic Anhydrase Inhibitor Coated Gold Nanoparticles Selectively Inhibit the Tumor-Associated Isoform IX over the Cytosolic Isozymes I and II. Journal of the American Chemical Society, 2008, 130, 16130-16131.	13.7	102

#	Article	IF	Citations
19	Carbonic Anhydrase Inhibitors:Â Hypoxia-Activatable Sulfonamides Incorporating Disulfide Bonds that Target the Tumor-Associated Isoform IXâ€. Journal of Medicinal Chemistry, 2006, 49, 5544-5551.	6.4	100
20	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5427-5433.	2.2	98
21	Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 397-401.	5.2	90
22	Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). Expert Opinion on Therapeutic Patents, 2018, 28, 493-504.	5.0	86
23	Carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 837-840.	2.2	81
24	Emerging trends in enzyme inhibition by multivalent nanoconstructs. Organic and Biomolecular Chemistry, 2015, 13, 9894-9906.	2.8	81
25	Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 561-580.	5.2	81
26	Rigid Pushâ^'Pull Oligo(p-Phenylene) Rods:Â Depolarization of Bilayer Membranes with Negative Membrane Potential. Journal of the American Chemical Society, 1999, 121, 7961-7962.	13.7	80
27	Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiotherapy and Oncology, 2013, 108, 523-528.	0.6	80
28	Carbonic Anhydrase Inhibitors:â€‰ Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates. Journal of Medicinal Chemistry, 2003, 46, 5471-5477.	6.4	79
29	A new Î²-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorganic and Medicinal Chemistry, 2011, 19, 1172-1178.	3.0	79
30	New Zinc Binding Motifs in the Design of Selective Carbonic Anhydrase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2006, 6, 921-936.	2.4	78
31	Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates. Journal of Medicinal Chemistry, 2013, 56, 8512-8520.	6.4	76
32	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series ofin vitrobreast cancer models. Oncotarget, 2015, 6, 24856-24870.	1.8	76
33	Design of Zinc Binding Functions for Carbonic Anhydrase Inhibitors. Current Pharmaceutical Design, 2008, 14, 615-621.	1.9	75
34	The sulfamide motif in the design of enzyme inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 27-47.	5.0	74
35	Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 321-324.	5.2	74
36	Carbonic Anhydrase Inhibitors:Â Synthesis and Inhibition of Cytosolic/Membrane-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Hydrazino Moieties. Journal of Medicinal Chemistry, 2005, 48, 2121-2125.	6.4	70

#	Article	IF	Citations
37	Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chemical Communications, 2016, 52, 11983-11986.	4.1	69
38	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-Î±-d-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 225-229.	2.2	68
39	A convenient synthesis of peracetylated glycosyl halides using bismuth(III) halides as catalysts. Carbohydrate Research, 1997, 297, 175-180.	2.3	66
40	Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. Chemical Communications, 2012, 48, 8177.	4.1	66
41	The importance of sulfur-containing motifs in drug design and discovery. Expert Opinion on Drug Discovery, 2022, 17, 501-512.	5.0	60
42	Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer. Bioorganic and Medicinal Chemistry, 2013, 21, 1419-1426.	3.0	58
43	Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4681-4685.	2.2	57
44	Carbonic Anhydrase Activators: Gold Nanoparticles Coated with Derivatized Histamine, Histidine, and Carnosine Show Enhanced Activatory Effects on Several Mammalian Isoforms. Journal of Medicinal Chemistry, 2011, 54, 1170-1177.	6.4	54
45	Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3302-3306.	2.2	52
46	Development of Potent Carbonic Anhydrase Inhibitors Incorporating Both Sulfonamide and Sulfamide Groups. Journal of Medicinal Chemistry, 2012, 55, 6776-6783.	6.4	52
47	Inhibition studies of a Î²-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2178-2182.	2.2	51
48	Carbonic anhydrases fromTrypanosoma cruziandLeishmania donovani chagasiare inhibited by benzoxaboroles. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 286-289.	5.2	50
49	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.6	49
50	Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranoseâ€“thioureido tails. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2685-2691.	2.2	48
51	Carbonic anhydrase inhibitors. Inhibition of the fungal Î²-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2642-2645.	2.2	47
52	Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents. Current Pharmaceutical Design, 2010, 16, 3310-3316.	1.9	47
53	Benzoxaboroles as Efficient Inhibitors of the Î²-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study. ACS Medicinal Chemistry Letters, 2017, 8, 1194-1198.	2.8	47
54	Design, Synthesis, and Pharmacological Evaluation of Pyridinic Analogues of Nimesulide as Cyclooxygenase-2 Selective Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 6749-6759.	6.4	46

#	Article	IF	Citations
55	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5775-5780.	2.2	46
56	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamidesâ€"a new zinc-binding function in the design of inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2353-2358.	2.2	46
57	Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies. Cells, 2020, 9, 629.	4.1	45
58	N-(tert-Butoxycarbonyl)-N-[4- (dimethylazaniumylidene)-1,4- dihydropyridin-1-ylsulfonyl]azanide: A New Sulfamoylating Agent. Structure and Reactivity toward Amines. Organic Letters, 2001, 3, 2241-2243.	4.6	44
59	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiffâ€™s bases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6014-6017.	2.2	44
60	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 579-584.	2.2	43
61	Designing carbonic anhydrase inhibitors for the treatment of breast cancer. Expert Opinion on Drug Discovery, 2015, 10, 591-597.	5.0	43
62	Carbonic Anhydrase-Encoded Dynamic Constitutional Libraries: Toward the Discovery of Isozyme-Specific Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 4853-4859.	6.4	40
63	Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1726-1731.	2.2	38
64	Homologation of carboxylic acids by arndt-eistert reaction under ultrasonic waves. Tetrahedron Letters, 1996, 37, 1781-1782.	1.4	37
65	Carbonic anhydrase inhibitors: Copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 836-841.	2.2	37
66	Synthesis of Multiply Substituted, Ion Channel Forming Octi(p-phenylene)s:â€‰ Theme and Variations. Organic Letters, 2000, 2, 37-39.	4.6	36
67	Brucella suis histidinol dehydrogenase: Synthesis and inhibition studies of a series of substituted benzylic ketones derived from histidine. Bioorganic and Medicinal Chemistry, 2007, 15, 4427-4433.	3.0	36
68	Inhibition of Carbonic Anhydrase IX: A New Strategy Against Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 693-702.	1.7	36
69	N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl] Azanide:â€‰ A New Sulfamoylating Agent. Structure and Reactivity toward Amines. Organic Letters, 2001, 3, 2939-2939.	4.6	33
70	Brucella suis carbonic anhydrases and their inhibitors: Towards alternative antibiotics?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 683-687.	5.2	33
71	Therapeutic applications of sulfamates. Expert Opinion on Therapeutic Patents, 2004, 14, 1273-1308.	5.0	31
72	Poly(amidoamine) Dendrimers with Carbonic Anhydrase Inhibitory Activity and Antiglaucoma Action. Journal of Medicinal Chemistry, 2015, 58, 4039-4045.	6.4	31

#	Article	IF	Citations
73	Cytotoxicity, DNA Damage, and Apoptosis Induced by New Fotemustine Analogs on Human Melanoma Cells in Relation to O6-Methylguanine DNA-Methyltransferase Expression. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 816-823.	2.5	29
74	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. Bioorganic and Medicinal Chemistry, 2009, 17, 3649-3652.	3.0	29
75	Inhibition of beta-carbonic anhydrases from the bacterial pathogen Brucella suis with inorganic anions. Journal of Inorganic Biochemistry, 2012, 110, 36-39.	3.5	29
76	Carbonic Anhydrase Inhibitors: Design of Membraneâ€Impermeant Copper(II) Complexes of DTPAâ€, DOTAâ€, and TETAâ€Tailed Sulfonamides Targeting the Tumorâ€Associated Transmembrane Isoform IX. ChemMedChem, 2008, 3, 1780-1788.	3.2	28
77	Carbonic anhydrase inhibitors: Crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mammalian isoforms Iâ€"XV. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3601-3605.	2.2	27
78	General synthesis of n-membered cyclic sulfamides. Tetrahedron, 2003, 59, 6051-6056.	1.9	26
79	Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5096-5100.	2.2	26
80	The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. Organic and Biomolecular Chemistry, 2016, 14, 4853-4858.	2.8	26
81	Insights into the binding mode of sulphamates and sulphamides to hCA II: crystallographic studies and binding free energy calculations. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1002-1011.	5.2	26
82	Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines. European Journal of Medicinal Chemistry, 2003, 38, 319-324.	5.5	25
83	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1683-1686.	2.2	25
84	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2359-2364.	2.2	25
85	Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3063-3066.	2.2	25
86	Benzoxaboroles: New Potent Inhibitors of the Carbonic Anhydrases of the Pathogenic Bacterium Vibrio cholerae. ACS Medicinal Chemistry Letters, 2020, 11, 2277-2284.	2.8	25
87	Carbonic anhydrase inhibitors: 2-Substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6332-6335.	2.2	24
88	Carbonic anhydrase activators: Activation of human isozymes I, II and IX with phenylsulfonylhydrazido l-histidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2440-2443.	2.2	23
89	Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4884-4887.	2.2	23
90	Fluorescent Silica Nanoparticles with Multivalent Inhibitory Effects towards Carbonic Anhydrases. Chemistry - A European Journal, 2015, 21, 10306-10309.	3.3	23

#	Article	IF	Citations
91	Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors. Current Topics in Medicinal Chemistry, 2007, 7, 835-848.	2.1	22
92	Targeting of the Brucella suis Virulence Factor Histidinol Dehydrogenase by Histidinol Analogues Results in Inhibition of Intramacrophagic Multiplication of the Pathogen. Antimicrobial Agents and Chemotherapy, 2007, 51, 3752-3755.	3.2	22
93	Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms I and II with (reduced) Schiffâ€™s bases incorporating sulfonamide, carboxylate and carboxymethyl moieties. Bioorganic and Medicinal Chemistry, 2014, 22, 2867-2874.	3.0	22
94	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	5.5	22
95	Carbonic Anhydrase Inhibitors. Comparison of Aliphatic Sulfamate/Bis-sulfamate Adducts with Isozymes II and IX as a Platform for Designing Tight-Binding, More Isoform-Selective Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5990-5998.	6.4	21
96	Effective Access to Multivalent Inhibitors of Carbonic Anhydrases Promoted by Peptide Bioconjugation. Chemistry - A European Journal, 2017, 23, 6788-6794.	3.3	21
97	Multivalent Carbonic Anhydrases Inhibitors. International Journal of Molecular Sciences, 2019, 20, 5352.	4.1	21
98	Interactions 500: Design, Implementation, and Evaluation of a Hybrid Board Game for Aiding Students in the Review of Intermolecular Forces During the COVID-19 Pandemic. Journal of Chemical Education, 2020, 97, 4049-4054.	2.3	21
99	Synthesis and properties of isocannabinoid and cholesterol derivatized rhamnosurfactants: application to liposomal targeting of keratinocytes and skin. European Journal of Medicinal Chemistry, 2005, 40, 1022-1029.	5.5	20
100	Zinc metalloenzymes as new targets against the bacterial pathogen Brucella. Journal of Inorganic Biochemistry, 2012, 111, 138-145.	3.5	20
101	Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators. Bioorganic and Medicinal Chemistry, 2014, 22, 4752-4758.	3.0	20
102	Carbonic Anhydrase Inhibitors as Novel Drugs against Mycobacterial Î²-Carbonic Anhydrases: An Update on In Vitro and In Vivo Studies. Molecules, 2018, 23, 2911.	3.8	20
103	Design, synthesis, inÂvitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 109-117.	5.2	20
104	Inhibition of carbonic anhydrases by a substrate analog: benzyl carbamate directly coordinates the catalytic zinc ion mimicking bicarbonate binding. Chemical Communications, 2018, 54, 10312-10315.	4.1	19
105	Bis-benzoxaboroles: Design, Synthesis, and Biological Evaluation as Carbonic Anhydrase Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 1205-1210.	2.8	19
106	Ferrier sulfamidoglycosylation of glycals catalyzed by nitrosonium tetrafluoroborate: Towards new carbonic anhydrase glycoinhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 6353-6359.	3.0	18
107	Carbonic anhydrase inhibitors: Design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3475-3480.	2.2	16
108	Anti-virulence Strategy against Brucella suis: Synthesis, Biological Evaluation and Molecular Modeling of Selective Histidinol Dehydrogenase Inhibitors. Organic and Biomolecular Chemistry, 2011, 9, 3681.	2.8	16

#	Article	IF	Citations
109	Dominant behaviours in the expression of human carbonic anhydrase hCA I activity. Chemical Communications, 2014, 50, 8043-8046.	4.1	16
110	Response to Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors. Biophysical Journal, 2021, 120, 178-181.	0.5	16
111	Synthese et N-Acylation Regiospecifique de 1,2,5-Thiadiazolidines 1,1-Dioxydes Chirales. Phosphorus, Sulfur and Silicon and the Related Elements, 2003, 178, 693-705.	1.6	15
112	Inclusion complexes of N-sulfamoyloxazolidinones with Î²-cyclodextrin. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 889-894.	2.2	15
113	Carbonic anhydrase inhibitors: The X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2795-2801.	2.2	15
114	Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents. Anti-Infective Agents in Medicinal Chemistry, 2008, 7, 169-179.	0.6	15
115	N-aryl-Nâ€™-ureido-O-sulfamates: Potent and selective inhibitors of the human Carbonic Anhydrase VII isoform with neuropathic pain relieving properties. Bioorganic Chemistry, 2019, 89, 103033.	4.1	15
116	Novel Re(I) tricarbonyl coordination compounds based on 2-pyridyl-1,2,3-triazole derivatives bearing a 4-amino-substituted benzenesulfonamide arm: synthesis, crystal structure, computational studies and inhibitory activity against carbonic anhydrase I, II, and IX isoformsâ€. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 773-782.	5.2	15
117	Nâ€Chlorosulfonyloxazolidinâ€2â€ones: Synthesis, Structure, and Reactivity Toward Aminoesters. Synthetic Communications, 2004, 34, 1653-1662.	2.1	14
118	Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2975-2979.	2.2	14
119	Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX inXenopusoocytes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1064-1073.	5.2	14
120	A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity. International Journal of Molecular Sciences, 2020, 21, 8405.	4.1	14
121	Design, implementation, and evaluation of a game-based application for aiding chemical engineering and chemistry students to review the organic reactions. Education for Chemical Engineers, 2021, 34, 106-114.	4.8	14
122	Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 â€“ 2021. Expert Opinion on Therapeutic Patents, 2022, 32, 1-12.	5.0	14
123	Thiolâ€“ene click chemistry for the synthesis of highly effective glycosyl sulfonamide carbonic anhydrase inhibitors. Chemical Communications, 2013, 49, 5699.	4.1	13
124	Inhibition of Î²-carbonic anhydrases from Brucella suis with C-cinnamoyl glycosides incorporating the phenol moiety. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 1017-1020.	5.2	13
125	Anion inhibitors of the Î²-carbonic anhydrase from the pathogenic bacterium responsible of tularemia, Francisella tularensis. Bioorganic and Medicinal Chemistry, 2017, 25, 4800-4804.	3.0	13
126	Reactions: An Innovative and Fun Hybrid Game to Engage the Students Reviewing Organic Reactions in the Classroom. Journal of Chemical Education, 2020, 97, 749-753.	2.3	13

#	Article	IF	Citations
127	Kinetic investigation on aqueous decomposition of 2-chloroethylnitrososulfamide. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1021-1027.	2.2	12
128	Synthesis and Pharmacological Evaluation of Novel Nitrobenzenic Thromboxane Modulators as Antiplatelet Agents Acting on Both the Alpha and Beta Isoforms of the Human Thromboxane Receptor. Journal of Medicinal Chemistry, 2006, 49, 3701-3709.	6.4	12
129	Carbonic anhydrase inhibitors; Fluorinated phenyl sulfamates show strong inhibitory activity and selectivity for the inhibition of the tumor-associated isozymes IX and XII over the cytosolic ones I and II. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5082-5085.	2.2	12
130	Synthesis of rhodamine Bâ€“benzenesulfonamide conjugates and their inhibitory activity against human Î±- and bacterial/fungal Î²-carbonic anhydrases. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5210-5213.	2.2	12
131	A spectrophotometric and thermodynamic study of the charge-transfer complexes of N-aryl-Nâ€²-isopropyloxycarbonylsulfamides with DDQ and TCNE. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, 108, 55-61.	3.9	12
132	Synthesis, Crystal Structure, Inhibitory Activity and Molecular Docking of Coumarins/Sulfonamides Containing Triazolyl Pyridine Moiety as Potent Selective Carbonic Anhydrase IX and XII Inhibitors. Crystals, 2021, 11, 1076.	2.2	12
133	A Simple, General and Efficient Method for O and N-Retinoylation. Application to The Synthesis of 2-Retinoyl-Lecithin. Synthetic Communications, 1998, 28, 2945-2958.	2.1	11
134	Inclusion complexes of 2-chloroethylnitrososulfamides (CENS) with Î²-cyclodextrin. European Journal of Medicinal Chemistry, 2004, 39, 79-84.	5.5	11
135	Carbonic Anhydrase Inhibitors: Aliphatic N-phosphorylated Sulfamates--A Novel Zinc-anchoring Group Leading to Nanomolar Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 275-278.	5.2	11
136	Binding of Carbonic Anhydrase IX to 45S rDNA Genes Is Prevented by Exportin-1 in Hypoxic Cells. BioMed Research International, 2015, 2015, 1-10.	1.9	11
137	A convenient method for the alkylation of sulfamides using alkyl bromides and Mitsunobu betaine. Tetrahedron Letters, 2001, 42, 601-603.	1.4	10
138	Synthesis and biological activity of glycosyl conjugates of N-(4-hydroxyphenyl)retinamide. Il Farmaco, 2001, 56, 319-324.	0.9	10
139	Hydroxylamine-O-sulfonamide is a versatile lead compound for the development of carbonic anhydrase inhibitors. Chemical Communications, 2015, 51, 11519-11522.	4.1	10
140	Brucella suishistidinol dehydrogenase: Synthesis and inhibition studies of substituted N-L-histidinylphenylsulfonyl hydrazide. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 357-361.	5.2	9
141	Structural basis for the rational design of new anti-Brucella agents: The crystal structure of the C366S mutant of l-histidinol dehydrogenase from Brucella suis. Biochimie, 2014, 97, 114-120.	2.6	9
142	Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series. ACS Medicinal Chemistry Letters, 2015, 6, 819-821.	2.8	9
143	ETUDE DE LA RÃ‰ACTION DE MICHAELISARBUZOV SOUS ACTIVATION ULTRASONORE. Phosphorus, Sulfur and Silicon and the Related Elements, 1997, 129, 83-88.	1.6	8
144	Metal-based carboxamide-derived compounds endowed with antibacterial and antifungal activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 517-526.	5.2	8

#	Article	IF	Citations
145	(Hetero)aryl substituted thiazol-2,4-yl scaffold as human carbonic anhydrase I, II, VII and XIV activators. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 224-229.	5.2	8
146	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopesâ€“6. Molecules, 2020, 25, 119.	3.8	8
147	Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation. Molecules, 2020, 25, 2347.	3.8	8
148	HSG400 â€“ Design, implementation, and evaluation of a hybrid board game for aiding chemistry and chemical engineering students in the review of stereochemistry during and after the COVID-19 pandemic. Education for Chemical Engineers, 2021, 36, 90-99.	4.8	8
149	One-Pot Synthesis of Nucleosides Using Bismuth(III) Bromide as Catalyst.. Synthetic Communications, 1998, 28, 603-606.	2.1	7
150	Carbonic Anhydrase Inhibitors: Glycosylsulfanilamides Act as Subnanomolar Inhibitors of the Human Secreted Isoform VI. Chemical Biology and Drug Design, 2009, 74, 636-639.	3.2	7
151	Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1498-1505.	5.2	7
152	Synthesis of new targretinÂ® analogues that induce apoptosis in leukemia HL-60 cells. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3529-3532.	2.2	6
153	Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1. Expert Opinion on Therapeutic Patents, 2013, 23, 757-760.	5.0	6
154	N-glycosyl-N-hydroxysulfamides as potent inhibitors of Brucella suis carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 1010-1012.	5.2	6
155	Design, synthesis and photoluminescent studies of new 1,5-benzodiazepines derivatives: Towards new ESIPT compounds. Tetrahedron, 2021, 86, 132078.	1.9	6
156	Efficient Synthesis of Chiral 1,1â€²â€Sulfonyl Bisaziridines. Synthetic Communications, 2006, 36, 2299-2305.	2.1	5
157	Carbonic anhydrase inhibitors: Gd(iii) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. New Journal of Chemistry, 2010, 34, 2139.	2.8	5
158	Oxo- and thiooxo-imidazo[1,5-c]pyrimidine molecule library: Beyond their interest in inhibition of Brucella suis histidinol dehydrogenase, a powerful protection tool in the synthesis of histidine analogues. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5008-5010.	2.2	5
159	Polyhedral Oligomeric Silsesquioxane (POSS) Bearing Glyoxylic Aldehyde as Clickable Platform Towards Multivalent Conjugates. Chemistry - A European Journal, 2017, 23, 17867-17869.	3.3	5
160	Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells. Leukemia and Lymphoma, 2018, 59, 460-468.	1.3	5
161	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopesâ€“7. Molecules, 2020, 25, 2968.	3.8	5
162	Synthesis of Substituted N-aryl-N-Sulfamoyloxazolidin-2-ones with Potential Antibacterial Activity. Recent Patents on Anti-infective Drug Discovery, 2007, 2, 131-139.	0.8	4

#	Article	IF	Citations
163	Synthesis and biological evaluation of a new class of anti-brucella compounds targeting histidinol dehydrogenase: Î±-O-arylketones and Î±-S-arylketones derived from histidine. MedChemComm, 2011, 2, 995.	3.4	4
164	Novel method of treating macular degeneration: a patent evaluation (WO2018/107005). Expert Opinion on Therapeutic Patents, 2019, 29, 749-752.	5.0	4
165	SYNTHESIS AND BIOLOGICAL ACTIVITY OF A RETINYL PHOSPHONIC ACID DERIVATIVE AN ANALOG OF RETINYL PHOSPHATE: HOMORETINYLPHOSPHONIC ACID. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 152, 241-256.	1.6	3
166	Carbonic anhydrase inhibitors. N-Cyanomethylsulfonamidesâ€"a new zinc binding group in the design of inhibitors targeting cytosolic and membrane-anchored isoforms. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 477-481.	5.2	3
167	Study on the Decomposition of 2-Chloroethylnitro- sosulfamides (CENS) in Serum Using HPLC On-line Solid Phase Extraction. Archiv Der Pharmazie, 2006, 339, 521-526.	4.1	3
168	Carbonic anhydrase IX inhibitors: fluorescent sulfonamides as therapeutic and diagnostic agents. Expert Opinion on Therapeutic Patents, 2007, 17, 1393-1396.	5.0	3
169	Carbonic Anhydrases as Esterases and Their Biotechnological Applications. , 2015, , 361-371.		3
170	Carbonic anhydrase inhibitors for the treatment of tumors. , 2019, , 331-365.		3
171	Carbonic Anhydrase Inhibitors Featuring a Porphyrin Scaffold: Synthesis, Optical and Biological Properties. European Journal of Organic Chemistry, 2022, 2022, .	2.4	3
172	1,5â€Benzodiazepines as a platform for the design of carbonic anhydrase inhibitors. Archiv Der Pharmazie, 2022, 355, 2100405.	4.1	3
173	New pyrophosphate analogues: a facile access to N-(O-alkyl-sulfamoyl)phosphoramidic acids via a simple and quantitative reaction of N-(O-alkylsulfamoyl)trimethylphospha-Î»5-azene with bromotrimethylsilane and water. Tetrahedron, 2004, 60, 2187-2190.	1.9	2
174	tert-ButylN-[N,N-bis(2-chloroethyl)sulfamoyl]-N-(2-chloroethyl)carbamate. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2543-o2544.	0.2	2
175	Inhibitors of Histidinol Dehydrogenases as Antibacterial Agents. , 0, , 937-949.		2
176	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors: a patent evaluation of US20160011199A1. Expert Opinion on Therapeutic Patents, 2016, 26, 1223-1226.	5.0	2
177	Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370). Expert Opinion on Therapeutic Patents, 2018, 28, 741-743.	5.0	2
178	The Hunt for Maya Purple: Revisiting Ancient Pigments Syntheses and Properties. Journal of Chemical Education, 2021, 98, 1389-1396.	2.3	2
179	Inhibitors of Selected Bacterial Metalloenzymes. Current Medicinal Chemistry, 2019, 26, 2690-2714.	2.4	2
180	Fluorescent Silica Nanoparticles with Multivalent Inhibitory Effects towards Carbonic Anhydrases. Chemistry - A European Journal, 2015, 21, 10249-10249.	3.3	1

#	Article	IF	Citations
181	Inhibitors of Histidinol Dehydrogenase. Topics in Medicinal Chemistry, 2016, , 35-46.	0.8	1
182	Metalloenzymes as Therapeutic Targets. Current Medicinal Chemistry, 2019, 26, 2556-2557.	2.4	1
183	Synthesis of New TargretinÂ® Analogues That Induce Apoptosis in Leukemia HL-60 Cells.. ChemInform, 2003, 34, no.	0.0	0
184	Carbonic Anhydrase Inhibitors: Inhibition of Cytosolic Isozymes I and II with Sulfamide Derivatives.. ChemInform, 2003, 34, no.	0.0	0
185	Synthesis and Biological Evaluation of Fotemustine Analogues on Human Melanoma Cell Lines.. ChemInform, 2003, 34, no.	0.0	0
186	Sulfamates and Their Therapeutic Potential. ChemInform, 2005, 36, no.	0.0	0
187	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Thioureido-Sulfanilyl Scaffolds.. ChemInform, 2005, 36, no.	0.0	0
188	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Tumor-Associated Carbonic Anhydrase Isozymes I, II, IX, and XII with N-Hydroxysulfamides â€" A New Zinc-Binding Function in the Design of Inhibitors.. ChemInform, 2005, 36, no.	0.0	0
189	APOBEC3G: A Promising Antiviral Target. , 0, , 981-987.		0
190	Expeditious Stereoselective Synthesis of l-Iminosugar Precursors via a Mitsunobu Reaction. Synlett, 2009, 2009, 978-980.	1.8	0
191	Selectivity Issues in the Design of CA Inhibitors. , 0, , 399-413.		0
192	Grafting of 4-aminomethylbenzensulfonamide-lipoic acid conjugate on gold nanoparticles. IOP Conference Series: Materials Science and Engineering, 2012, 28, 012032.	0.6	0
193	Carbonic Anhydrase XIV: Structure, Functions, and Potential Medical Applications. , 2015, , 221-237.		0
194	Nanostructures and innovative delivery systems for overcoming cancer resistance. , 2021, , 185-201.		0
195	Abstract 5088: Blocking mesenchymal stem cell-induced CAIX hampers metastatic potential and chemoresistance in TNBC. , 2020, , .		0